PPT-MDR and XDR TB

Bruce A Bush MD Regional Tuberculosis Consultant Pennsylvania Department of Health Senior Vice President for Medical Affairs Indiana Regional Medical Center Disclosures I do not have any financial arrangements or affiliations with a commercial entity. Staphylococcus . aureus. On Door Handles In . Ahmadu. Bello University, Zaria, Nigeria.. Onaolapo. . J. A. .*, . Afolabi. . O. . E . and . Igwe. J. . C.. Department . of Pharmaceutics and Pharmaceutical Microbiology, . Basics. Disclaimer. The information contained in this slide deck represents the current view of Microsoft Corporation on the issues discussed as of the date of publication. Because Microsoft must respond to changing market conditions, it should not be interpreted to be a commitment on the part of Microsoft, and Microsoft cannot guarantee the accuracy of any information presented after the date of publication.. Scott K. . Heysell. MD, MPH. (no disclosures). Why do we need new drugs/ regimens?. ▪Isoniazid and pyrazinamide remain some of the most . toxic. antibiotics prescribed for infectious disease . -. Scott K. . Heysell. MD, MPH. (no disclosures). Why do we need new drugs/ regimens?. ▪Isoniazid and pyrazinamide remain some of the most . toxic. antibiotics prescribed for infectious disease . -. XDR. -TB?. At least 2 years (the same as . MDR. -TB). . Doctors will monitor people with any form of confirmed drug resistant TB very carefully. . Treatment will continue for as long as it takes for the patient to be cured, if that patient CAN be cured. . F. uture . of TB . Therapy. Putting science to work for better, faster TB cures. Achieving maximum impact will require:. Short, simple regimens that are adopted, available and affordable.. Ideally, a universal regimen consisting of all novel drugs that is effective in all people with active TB. . Mekong . Sub-region. CAP-TB PROJECT. . Strengthening the health system through basic building blocks for TB control . CAP-TB Strategic Model. Integration with the health system for TB control and prevention. Dr Francesca Conradie . Treatment of Drug sensitive TB. 6 months of treatment consisting of . Intensive phase- INH, Rif, PZA and Ethambutol for 2 months. Continuation phase- INH and Rif. Medications are co-formulated. Naira Dekhil. 1. , . Besma. Mhenni. 1. , Raja Haltiti. 2. , and . Helmi. Mardassi. 1. . (speaker).  . 1. Unit of Typing & Genetics of . Mycobacteria. , . Institut. Pasteur de Tunis, . Tunisia. MMed. (. Fam. Med) (MED). Director, . Drug-Resistant TB, TB & HIV . Models of Care for People with Drug-Resistant TB: Advancements in South Africa. Background and TB burden in South Africa. Models . , Senior Medical Officer at Helen Joseph Hospital . Shorter, Simpler Treatment for XDR-TB . One day . of XDR treatment today . Treatment duration: 2+ years. One week . of BPaL regimen in Nix-TB trial. Echols RM, Tomayko JF, Dudley MN, Dane A. Progress in the fight against multidrug-resistant bacteria 2005-2016: Modern non-inferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance. . Murase Y, Maeda S, Yamada H, Ohkado A, Chikamatsu K, Mizuno K, et al. Clonal Expansion of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, Japan. Emerg Infect Dis. 2010;16(6):948-954. https://doi.org/10.3201/eid1606.091844. per la gestione della tubercolosi. Marina Tadolini . Clinica di Malattie Infettive – Prof. Viale. Dipartimento di Scienze Mediche e Chirurgiche. Alma Mater . Studiorum. Università di Bologna. . in .